Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 12:23:1768-1774.
doi: 10.12659/msm.900977.

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma

Affiliations

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma

Yehui Chen et al. Med Sci Monit. .

Abstract

BACKGROUND Prostate carcinoma (PCa) is often not diagnosed until advanced disease with bone metastasis. Predictive factors for bone metastasis are required to improve patient outcomes. The study aimed to analyze the factors associated with bone metastases in newly diagnosed patients with PCa. MATERIAL AND METHODS This was a retrospective study of 80 patients newly diagnosed with PCa by pathological examination between January 2012 and December 2014. Bone metastases were diagnosed by positron emission computed tomography. Clinical data, serological laboratory results, and pathological examination results were collected. RESULTS Among the 80 patients, 45 (56%) had bone metastases. Age, serum alkaline phosphatase, prostate-specific antigen (PSA), erythrocyte sedimentation rate, PCa tissue Gleason score, androgen receptor (AR) expression, and Ki-67 expression were higher in patients with bone metastasis compared with those without (all P<0.05). Multivariate logistic regression showed that PSA (OR: 1.005; 95%CI: 1.001-1.010; P=0.016), Gleason score (OR: 4.095; 95%CI: 1.592-10.529; P=0.003), and AR expression (OR: 14.023; 95%CI: 3.531-55.6981; P=0.005) were independently associated with bone metastases. Cut-off values for PSA, Gleason score, and AR expression were 67.1 ng/ml (sensitivity: 55.6%; specificity: 97.1%), 7.5 (sensitivity: 75.6%; specificity: 82.9%), and 2.5 (sensitivity: 84.0%; specificity: 91.4%), respectively. CONCLUSIONS PSA, Gleason score, and AR expression in PCa tissues were independently associated with PCa bone metastases. These results could help identifying patients with PCa at high risk of bone metastases.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Androgen receptor (AR) and Ki-67 expressions in prostate carcinoma tissues were determined by immunohistochemistry. (A) AR negative (–); (B) AR weak positive (+); (C) AR moderate positive (++); (D) AR strong positive (+++); (E) Ki-67 negative; (F) Ki-67 positive. Magnification: ×100.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curves of prostate-specific antigen (PSA), Gleason score, and the prostate carcinoma tissue AR-positive expression for the prediction of bone metastasis in patients with prostate carcinoma. PSA (cut-off value: 67.1 ng/mL; AUC: 0.819; sensitivity: 55.6%; specificity: 97.1%). Gleason score (cut-off value: 7.5; AUC: 0.866; sensitivity: 75.6%; specificity: 82.9%). AR (cut-off value: 2.5; AUC: 0.894; sensitivity: 84.0%; specificity: 91.4%).

Similar articles

Cited by

References

    1. Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer Chemother Pharmacol. 2013;71:1629–34. - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer. Version 2.2014. Fort Washington: National Comprehensive Cancer Network; 2014.
    1. Graham J, Kirkbride P, Cann K, et al. Prostate cancer: Summary of updated NICE guidance. BMJ. 2014;348:f7524. - PubMed
    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64:9–29. - PubMed
    1. Bell KJ, Del Mar C, Wright G, et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015;137:1749–57. - PMC - PubMed

MeSH terms